361 related articles for article (PubMed ID: 32278840)
1. A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer.
Hird AE; Magee DE; Bhindi B; Ye XY; Chandrasekar T; Goldberg H; Klotz L; Fleshner N; Satkunasivam R; Klaassen Z; Wallis CJD
Clin Genitourin Cancer; 2020 Oct; 18(5):343-350. PubMed ID: 32278840
[TBL] [Abstract][Full Text] [Related]
2. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
Mori K; Mostafaei H; Pradere B; Motlagh RS; Quhal F; Laukhtina E; Schuettfort VM; Abufaraj M; Karakiewicz PI; Kimura T; Egawa S; Shariat SF
Int J Clin Oncol; 2020 Nov; 25(11):1892-1900. PubMed ID: 32924096
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis.
Chen X; Wang Q; Pan Y; Wang S; Li Y; Zhang H; Xu M; Zhou H; Liu X
Front Endocrinol (Lausanne); 2023; 14():1134719. PubMed ID: 36967752
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis.
Zhang X; Zhang G; Wang J; Bi J
Front Endocrinol (Lausanne); 2023; 14():1131033. PubMed ID: 36843606
[TBL] [Abstract][Full Text] [Related]
5. Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison.
Chowdhury S; Oudard S; Uemura H; Joniau S; Dearden L; Capone C; Van Sanden S; Diels J; Hadaschik BA
Adv Ther; 2022 Jan; 39(1):518-531. PubMed ID: 34797506
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis.
Kumar J; Jazayeri SB; Gautam S; Norez D; Alam MU; Tanneru K; Bazargani S; Costa J; Bandyk M; Ganapathi HP; Koochekpour S; Balaji KC
Urol Oncol; 2020 Nov; 38(11):826-834. PubMed ID: 32605736
[TBL] [Abstract][Full Text] [Related]
7. Novel Androgen Receptor Inhibitors in Non-Metastatic, Castration-Resistant Prostate Cancer: A Systematic Review and Network Meta-Analysis.
Mulati Y; Fan Y; Yu W; Zhang Q; He Z
Front Oncol; 2021; 11():733202. PubMed ID: 34722276
[TBL] [Abstract][Full Text] [Related]
8. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
Fallah J; Zhang L; Amatya A; Gong Y; King-Kallimanis B; Bhatnagar V; Weinstock C; Suzman DL; Agrawal S; Chang E; Anscher MS; Chi DC; Xu JX; Brewer JR; Brave MH; Hadadi M; Theoret MR; Kluetz PG; Goldberg KB; Ibrahim A; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L; Singh H
Lancet Oncol; 2021 Sep; 22(9):1230-1239. PubMed ID: 34310904
[TBL] [Abstract][Full Text] [Related]
9. Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
Wenzel M; Nocera L; Collà Ruvolo C; Würnschimmel C; Tian Z; Shariat SF; Saad F; Tilki D; Graefen M; Kluth LA; Briganti A; Mandel P; Montorsi F; Chun FKH; Karakiewicz PI
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):139-148. PubMed ID: 34054128
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.
Yanagisawa T; Rajwa P; Kawada T; Mori K; Fukuokaya W; Petrov P; Quhal F; Laukhtina E; von Deimling M; Bianchi A; Majdoub M; Pradere B; Kramer G; Kimura T; Shariat SF
J Urol; 2023 Sep; 210(3):416-429. PubMed ID: 37339479
[TBL] [Abstract][Full Text] [Related]
11. The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect Comparison.
Shore N; Jiang S; Garcia-Horton V; Terasawa E; Steffen D; Chin A; Ayyagari R; Partridge J; Waldeck AR
Adv Ther; 2022 Nov; 39(11):5025-5042. PubMed ID: 36028656
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial.
Bögemann M; Shore ND; Smith MR; Tammela TLJ; Ulys A; Vjaters E; Polyakov S; Jievaltas M; Luz M; Alekseev B; Lebret T; Schostak M; Verholen F; Le Berre MA; Srinivasan S; Ortiz J; Mohamed AF; Sarapohja T; Fizazi K
Eur Urol; 2023 Mar; 83(3):212-221. PubMed ID: 36089529
[TBL] [Abstract][Full Text] [Related]
13. Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer.
Chowdhury S; Oudard S; Uemura H; Joniau S; Pilon D; Ladouceur M; Behl AS; Liu J; Dearden L; Sermon J; Van Sanden S; Diels J; Hadaschik BA
Adv Ther; 2020 Jan; 37(1):501-511. PubMed ID: 31813086
[TBL] [Abstract][Full Text] [Related]
14. Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
Tombal B; Sternberg CN; Hussain M; Ganguli A; Li Y; Sandin R; Bhadauria H; Oh M; Saad F
ESMO Open; 2022 Jun; 7(3):100510. PubMed ID: 35714477
[TBL] [Abstract][Full Text] [Related]
15. Systemic Management for Nonmetastatic Castration-resistant Prostate Cancer: A Systematic Review and Network Meta-Analysis.
Liu Z; Zhang T; Ma Z; Zheng S; Chen J; Wu Z; Zheng X; Li X; Liu Z
Am J Clin Oncol; 2020 Apr; 43(4):288-297. PubMed ID: 31972568
[TBL] [Abstract][Full Text] [Related]
16. Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide.
Wallis CJD; Chandrasekar T; Goldberg H; Klotz L; Fleshner N; Satkunasivam R; Klaassen Z
Eur Urol Oncol; 2018 Aug; 1(3):238-241. PubMed ID: 31102627
[TBL] [Abstract][Full Text] [Related]
17. Cost-Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China.
Ming J; Wu Y; Han R; Xu X; Waldeck R; Hu S
Adv Ther; 2023 Mar; 40(3):1087-1103. PubMed ID: 36630046
[TBL] [Abstract][Full Text] [Related]
18. Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN.
Saad F; Small EJ; Feng FY; Graff JN; Olmos D; Hadaschik BA; Oudard S; Londhe A; Bhaumik A; Lopez-Gitlitz A; Thomas S; Mundle SD; Chowdhury S; Smith MR
Eur Urol; 2022 Feb; 81(2):184-192. PubMed ID: 34916086
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis.
Wang L; Paller CJ; Hong H; De Felice A; Alexander GC; Brawley O
JAMA Oncol; 2021 Mar; 7(3):412-420. PubMed ID: 33443584
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.
Smith MR; Antonarakis ES; Ryan CJ; Berry WR; Shore ND; Liu G; Alumkal JJ; Higano CS; Chow Maneval E; Bandekar R; de Boer CJ; Yu MK; Rathkopf DE
Eur Urol; 2016 Dec; 70(6):963-970. PubMed ID: 27160947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
